💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Luliconazole

CHEMBL2105689 Phase 4 Approved Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
354.3 g/mol
LogP
4.0
Phase
4

This topical azole antifungal is used to treat fungal skin infections including athlete's foot, jock itch, and ringworm by blocking a key enzyme in the synthesis of fungal cell membranes. Its formulation allows for a short treatment course, often just one application daily for one to two weeks.

Molecular Weight

354.3000 g/mol

LogP

4.00

TPSA

92.20 Ų

Lipinski RO5

Pass

Mechanism of Action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H9Cl2N3S2

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
Rotatable Bonds

                        
2

                    

                    
                    
                    

                        
Heavy Atoms

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
This topical azole antifungal is used to treat fungal skin infections including athlete's foot, jock itch, and ringworm by blocking a key enzyme in the synthesis of fungal cell membranes. Its formulation allows for a short treatment course, often just one application daily for one to two weeks.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Luliconazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2105689.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3003141.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.